Accordingly, targeting DNA methylation by HMAs in combination with the BCL2 apoptosis regulator (BCL-2) inhibitor venetoclax has recently become a standard therapeutic approach in the elderly and chemotherapy-unfit AML population [31]. This evidence concerns the gene BCL2 and acute myeloid leukemia.